Altered elastogenesis by Tsk fibrillin-1 and in SSc
Project Number5R01AR051089-02
Contact PI/Project LeaderLAFYATIS, ROBERT A
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by applicant): A large duplication in the fibrillin-1 gene (Tsk fibrillin-1) is responsible for the phenotype of the Tsk mouse, a model for skin disease in human systemic sclerosis (SSc). The best defined function of fibrillin is in supporting elastic fibers and we have recently found that Tsk mice show markedly increased hypodermal elastic fibers associated with striking changes in fibulin-2 and fibulin-5, proteins that regulate formation of elastic fibers. We are investigating the hypotheses that altered hypodermal deposition of fibulins causes skin tethering in Tsk mice and that altered dermal fibulin deposition increases elastic fibers in human SSc. We will study the effect of Tsk fibrillin-1 on fibulin-2 and -5 matrices by staining cells conditionally expressing Tsk-fibrillin-1. We will test the importance of fibulin-2 on Tsk skin tethering and altered elastogenesis by breeding Tsk mice to fibulin-2 deleted mice, we will also study the effect of fibulin-2 on elastogenesis in fibroblasts overexpressing or deleted of fibulin-2 in cell culture. Fibrillin associates with several other matrix proteins, including MAGP-2. We have found markedly increased MAGP-2 matrix in the skin of Tsk mice and human SSc. Upon expression of Tsk fibrillin-1 in cell lines, we find increased MAGP-2 and collagen matrices, suggesting that Tsk fibrillin-1 might augment collagen deposition through increased MAGP-2. The effect of increased MAGP-2 expression on collagen, fibulin and elastic fiber matrices will be studied in cell lines and transgenic mice. TGF-beta may interact indirectly with fibrillin-1 through latent TGF-beta binding proteins and TGF-beta regulates fibrillin-1 and MAGP-2 matrices in vitro. Since these are features of Tsk dermal pathology, the importance of TGF-beta on the Tsk phenotype and altered elastogenesis will be tested by examining MAGP-2 and fibulin-2 expresssion in Tsk mice bred to smadS deleted or fibroblast-targeted TGF-beta Rll deleted mice. Fibroblast cultures from these mice will also be examined for alterations in TGF-beta activity, and MAGP-2 and fibulin-2 mRNA expression. LTBP-1 or LTBP-4 will be examined as possible mediators of Tsk fibrillin-1 activation of TGF-beta signaling. Together these studies should help clarify the pathogenesis of altered elastogenesis and fibrosis associated with Tsk fibrillin-1. These findings will be correlated with studies on human SSc skin.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
20-August-2005
Project End Date
31-July-2010
Budget Start Date
01-August-2006
Budget End Date
31-July-2007
Project Funding Information for 2006
Total Funding
$208,170
Direct Costs
$128,898
Indirect Costs
$79,272
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$208,170
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR051089-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR051089-02
Patents
No Patents information available for 5R01AR051089-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR051089-02
Clinical Studies
No Clinical Studies information available for 5R01AR051089-02
News and More
Related News Releases
No news release information available for 5R01AR051089-02
History
No Historical information available for 5R01AR051089-02
Similar Projects
No Similar Projects information available for 5R01AR051089-02